- Home
- UPB vs GHRS Comparison
UPB vs GHRS Comparison
Compare UPB & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPB
- GHRS
- Stock Information
- Founded
- UPB 2021
- GHRS 2018
- Country
- UPB United States
- GHRS Ireland
- Employees
- UPB N/A
- GHRS N/A
- Industry
- UPB
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- UPB
- GHRS Health Care
- Exchange
- UPB NYSE
- GHRS Nasdaq
- Market Cap
- UPB 521.3M
- GHRS 583.1M
- IPO Year
- UPB 2024
- GHRS 2021
- Fundamental
- Price
- UPB $10.84
- GHRS $12.00
- Analyst Decision
- UPB Strong Buy
- GHRS Strong Buy
- Analyst Count
- UPB 4
- GHRS 8
- Target Price
- UPB $56.50
- GHRS $30.63
- AVG Volume (30 Days)
- UPB 405.0K
- GHRS 155.5K
- Earning Date
- UPB 05-06-2025
- GHRS 05-08-2025
- Dividend Yield
- UPB N/A
- GHRS N/A
- EPS Growth
- UPB N/A
- GHRS N/A
- EPS
- UPB N/A
- GHRS N/A
- Revenue
- UPB $2,296,000.00
- GHRS N/A
- Revenue This Year
- UPB N/A
- GHRS N/A
- Revenue Next Year
- UPB N/A
- GHRS N/A
- P/E Ratio
- UPB N/A
- GHRS N/A
- Revenue Growth
- UPB N/A
- GHRS N/A
- 52 Week Low
- UPB $5.14
- GHRS $6.00
- 52 Week High
- UPB $29.46
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- UPB N/A
- GHRS 53.18
- Support Level
- UPB N/A
- GHRS $10.66
- Resistance Level
- UPB N/A
- GHRS $12.28
- Average True Range (ATR)
- UPB 0.00
- GHRS 0.94
- MACD
- UPB 0.00
- GHRS 0.01
- Stochastic Oscillator
- UPB 0.00
- GHRS 51.47
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.